Login / Signup

Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program.

Linsey U GaniEric LauAndrea On Yan LukLeorino SobrepenaQuang Khanh TranJothydev KesavadevWeiping JiaWeinan YuChiu Chi TsangMonojitketan MukhopadhyaySujeet JhaWayne SheuYoon Kun HoThy Khue NguyenRisa OzakiWing Yee SoChristine KwanAmy W C FuRoberto MirasolSanjeev Ratnakar PhatakKanakatte Mylariah Prasanna KumarSosale AravindHari JanakiramanJuliana C N Channull null
Published in: Journal of diabetes investigation (2018)
Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes.
Keyphrases
  • glycemic control
  • type diabetes
  • blood glucose
  • weight loss
  • insulin resistance
  • quality improvement
  • cardiovascular disease
  • electronic health record
  • metabolic syndrome
  • big data
  • skeletal muscle
  • adipose tissue